Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers

The primary objective is to assess the effect of vaccination with neopeptide-loaded dendritic cells on disease-free survival (DFS) compared to placebo in LS subjects who are known to be carrier of a germline MMR-gene mutation with no signs of disease.

NCT Number	NCT07609901
Lead Sponsor	Radboud University Medical Center Collaborators: Dutch National Health Care Institute
Conditions	Lynch Syndrome
Enrollment	372 participants
Start Date	2026-10-01
Primary Completion	2032-10-01 (estimated)
Study Completion	2032-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-27